|
Anacardic acid
|
漆樹(shù)酸
|
16611-84-0
|
|
BEZ235
|
NVP-BEZ235
|
915019-65-7
|
|
API-1
|
4-Amino-5,6,7,8-tetrahydro-5-oxo-8-(β-D-ribofuranosyl)pyrido[2,3-d]pyrimidine-6-carboxamide
|
36707-00-3
|
|
PI-3065
|
PI-3065
|
955977-50-1
|
|
Serabelisib
|
[6-(2-氨基-5-苯并惡唑基)咪唑并[1,2-A]吡啶-3-基]-4-嗎啉基甲酮
|
1268454-23-4
|
|
Rapamycin
|
雷帕霉素
|
53123-88-9
|
|
Presatovir
|
GS-5806
|
1353625-73-6
|
|
Lifirafenib
|
LIFIRAFENIB
|
1446090-79-4
|
|
CU-T12-9
|
CU-T12-9
|
1821387-73-8
|
|
YKL-05-099
|
化合物YKL-05-099
|
1936529-65-5
|
|
DDD107498
|
DDD107498
|
1469439-69-7
|
|
Givinostat (ITF2357)
|
N-[4-[(羥基氨基)羰基]苯基]氨基甲酸 [6-[(二乙基氨基)甲基]-2-萘基]甲酯鹽酸鹽水合物
|
732302-99-7
|
|
Isoxazole 9 (ISX-9)
|
ISX 9
|
832115-62-5
|
|
AZD5363
|
4-氨基-N-[(1S)-1-(4-氯苯基)-3-羥基丙基]-1-(7H-吡咯并[2,3-D]嘧啶-4-基)-4-哌啶甲酰胺
|
1143532-39-1
|
|
GSK-J4 Hydrochloride
|
GSK-J4 鹽酸鹽
|
1797983-09-5
|
|
Liproxstatin-1
|
利普司他丁-1
|
950455-15-9
|
|
RK-33
|
RK-33
|
1070773-09-9
|
|
PF-9366
|
PF-9366
|
72882-78-1
|
|
CM-272
|
化合物CM-272
|
1846570-31-7
|
|
Veliparib
|
維利帕尼
|
912444-00-9
|
|
AZ 628
|
AZ 628
|
878739-06-1
|
|
MRT67307
|
N-[3-[[5-環(huán)丙基-2-[[3-(4-嗎啉基甲基)苯基]氨基]-4-嘧啶基]氨基]丙基]環(huán)丁烷甲酰胺
|
1190378-57-4
|
|
UNC0638
|
UNC0638
|
1255580-76-7
|
|
AR7
|
CS-2649
|
80306-38-3
|
|
HTH-01-015
|
HTH-01-015
|
1613724-42-7
|
|
BAM 15
|
CS-2890
|
210302-17-3
|
|
1,3-Benzenediol, 4-[1-(2-propenyl)-7-(trifluoromethyl)-1H-indazol-3-yl]-
|
1,3-Benzenediol, 4-[1-(2-propenyl)-7-(trifluoromethyl)-1H-indazol-3-yl]-
|
669764-18-5
|
|
Pyrimorph
|
丁吡嗎啉
|
868390-90-3
|
|
R-10015
|
METHYL 2-(1-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PIPERIDIN-4-YL)-1H-BENZO[D]IMIDAZOLE-6-CARBOXYLATE
|
2097938-51-5
|
|
TK216
|
TK216
|
1903783-48-1
|
|
VPC-80051
|
1H-Indazole-3-carboxamide, N-[1-(3,4-difluorophenyl)ethyl]-
|
877969-69-2
|
|
Losmapimod
|
Losmapimod (GW856553X)
|
585543-15-3
|
|
MM-102
|
MM-102
|
1417329-24-8
|
|
1-(2,4-Dichlorophenyl)-N-1-piperidinyl-4-[[(1-pyrrolidinylsulfonyl)amino]methyl]-5-[5-[2-[4-(trifluoromethyl)phenyl]ethynyl]-2-thienyl]-1H-pyrazole-3-carboxamide
|
1-(2,4-二氯苯基)-N-1-哌啶基-4-[[(1-吡咯烷基磺?；?氨基]甲基]-5-[5-[2-[4-(三氟甲基)苯基]乙炔基]-2-噻吩基]-1H-吡唑-3-甲酰胺
|
1429239-98-4
|
|
Aldose reductase-IN-1
|
AT-001
|
1355612-71-3
|
|
MK2-IN-3
|
2-[2-(3-quinolyl)-4-pyridyl]-1,5,6,7-tetrahydropyrrolo[3,2-c]pyridin-4-one
|
724711-21-1
|
|
PythiDC
|
化合物PYTHIDC
|
1821370-71-1
|
|
Mizagliflozin (KWA 0711)
|
Mizagliflozin
|
666843-10-3
|
|
PRE-084 hydrochloride
|
1-苯基環(huán)己烷羧酸 2-(4-嗎啉基)乙基酯鹽酸鹽
|
75136-54-8
|
|
AnsamitocinP-3
|
安絲菌素 P 3
|
66584-72-3
|
|
UPF 1069
|
5-(2-氧代-2-苯基乙氧基)-1(2H)-異喹啉酮
|
1048371-03-4
|
|
A66
|
A66
|
1166227-08-2
|
|
HDAC6 inhibitor
|
HDAC6 Inhibitor
|
1045792-66-2
|
|
NIBR-0213
|
NIBR 0213
|
1233332-14-3
|
|
Vactosertib (TEW-7197)
|
EW-7197
|
1352608-82-2
|
|
MBQ-167
|
MBQ 167;MBQ167
|
2097938-73-1
|
|
WYC-209
|
4,5-二(羥甲基)-2-苯基-1H-咪唑
|
2131803-90-0
|
|
FMK
|
FMK
|
821794-92-7
|
|
KU-60019
|
KU-60019
|
925701-49-1
|
|
VE-821
|
3-氨基-6-[4-(甲基磺酰基)苯基]-N-苯基-2-吡嗪甲酰胺
|
1232410-49-9
|
|
DCC-2036
|
N-[3-叔丁基-1-(喹啉-6-基)-1H-吡唑-5-基]-N'-[2-氟-4-[(2-(甲基氨基甲?；?吡啶-4-基)氧]苯基]脲
|
1020172-07-9
|
|
A-674563
|
A-674563
|
552325-73-2
|
|
BGT226 (NVP-BGT226) maleate
|
NVP-BGT226
|
1245537-68-1
|
|
BYL719
|
阿培利司
|
1217486-61-7
|
|
GSK2636771
|
GSK2636771
|
1372540-25-4
|
|
GDC-0068
|
帕他色替
|
1001264-89-6
|
|
HS-173
|
HS-173
|
1276110-06-5
|
|
Elacestrant dihydrochloride
|
RAD-1901
|
1349723-93-8
|
|
VPS34 inhibitor 1 (Compound 19)
|
VPS34
|
1383716-46-8
|
|
PF-06726304
|
PF-06726304
|
1616287-82-1
|
|
RY785
|
化合物RY785
|
689297-68-5
|
|
BI-1347
|
BI-1347
|
2163056-91-3
|
|
RU-301
|
RU-301
|
1110873-99-8
|
|
Tm2-115
|
TM2-115
|
1197196-47-6
|
|
Nilotinib (AMN-107)
|
尼羅替尼
|
641571-10-0
|
|
VX-150
|
N-[1,2-二氫-2-氧代-1-[(膦酰氧基)甲基]-4-吡啶基]-2-(4-氟-2-甲基苯氧基)-4-(三氟甲基)苯甲酰胺
|
1793080-72-4
|
|
CU-CPT-8m
|
CPD1578
|
125079-83-6
|
|
Bosutinib (SKI-606)
|
伯舒替尼
|
380843-75-4
|
|
BMPsignalingagonistsb4
|
SB 4
|
100874-08-6
|
|
UT-34
|
UT-34
|
2168525-92-4
|
|
DTHIB
|
Urea, N-(4-chloro-3-nitrophenyl)-N'-(4-fluorophenyl)-
|
897326-30-6
|
|
Bardoxolone
|
2-氰基-3,12-二氧代齊墩果-1,9-二烯-28-酸
|
218600-44-3
|
|
PS 48
|
(Z)-5-(4-氯苯基)-3-苯基戊-2-烯酸
|
1180676-32-7
|
|
XL765
|
XL765
|
1349796-36-6
|
|
GSK-J1
|
N-[2-(2-吡啶基)-6-(1,2,4,5-四氫-3H-3-苯并氮雜卓-3-基)-4-嘧啶基]-BETA-丙氨酸
|
1373422-53-7
|
|
IPI-3063
|
化合物IPI-3063
|
1425043-73-7
|
|
SJ000291942
|
SJ000291942
|
425613-09-8
|
|
NI 42
|
NI-42
|
1884640-99-6
|
|
Go 6983
|
3-[1-[3-(二甲基氨基)丙基]-5-甲氧基-1H-吲哚-3-基]-4-(1H-吲哚-3-基)-1H-吡咯-2,5-二酮
|
133053-19-7
|
|
Sirtinol
|
2-[[(2-羥基-1-萘基)亞甲基]氨基]-N-(1-苯基乙基)苯甲酰胺
|
410536-97-9
|
|
MK-4827 (Niraparib)
|
尼拉帕尼
|
1038915-60-4
|
|
TCS JNK 6o
|
JNK INHIBITOR VIII (TCS JNK 6O)
|
894804-07-0
|
|
IRAK inhibitor 1
|
環(huán)巴胺抑制劑 1
|
1042224-63-4
|
|
ICA-105574
|
化合物ICA-105574
|
316146-57-3
|
|
CBL0137
|
1,1'-(9-(2-(異丙基氨基)乙基)-9H-咔唑-3,6-二基)雙乙烷-1-酮
|
1197996-80-7
|
|
Takinib
|
1111556-37-6
|
1111556-37-6
|
|
HS-1793
|
化合物HS-1793
|
927885-00-5
|
|
SU5204
|
su5204
|
186611-11-0
|
|
MRT68921 HCl
|
化合物MRT68921 DIHYDROCHLORIDE
|
2080306-21-2
|
|
Enzastaurin (LY317615)
|
恩扎妥林
|
170364-57-5
|
|
Sotrastaurin
|
3-(1H-吲哚-3-基)-4-[2-(4-甲基哌嗪-1-基)喹唑啉-4-基]吡咯-2,5-二酮
|
425637-18-9
|
|
Thiazovivin
|
THIAZOVIVIN
|
1226056-71-8
|
|
INK-128
|
3-(2-氨基-5-苯并惡唑基)-1-(1-甲基乙基)-1H-吡唑并[3,4-D]嘧啶-4-胺
|
1224844-38-5
|
|
A-443654
|
(ALPHAS)-ALPHA-[[[5-(3-甲基-1H-吲唑-5-基)-3-吡啶基]氧基]甲基]-(S)-1H-吲哚-3-乙胺
|
552325-16-3
|
|
IKK-16 (IKK Inhibitor VII)
|
IKK-16
|
873225-46-8
|
|
WZ 4003
|
WZ4003
|
1214265-58-3
|
|
GSK106 hydrochloride
|
GSK106 (hydrochloride)
|
1652591-82-6
|
|
ML385
|
ML385
|
846557-71-9
|
|
WM 1119
|
化合物WM-1119
|
2055397-28-7
|
|
LY-2940094
|
BTRX-246040
|
1307245-86-8
|